Our results suggest that the change in the PSA level at an early stage after the initiation of ADT may have been a risk factor for poor patient outcomes even in recent years when various treatment options including novel anti-androgens, chemotherapies and vaccines became available for advanced prostate cancer. The gene discussed is KLK3; the disease is prostate cancer.